



BSW Formulary Update – June/July 2022

New additions to BSWformulary

- [Calcipotriol 50microgram/g with betamethasone 0.5% cream \(Wynzora®\)](#) – Added as a second line option for mild to moderate psoriasis vulgaris, including scalp psoriasis, in adults. **Green** TLS.
- [Tafluprost 15microgram/ml + timolol 5mg/ml eye drops](#) – Added as a cost-effective combination (beta-blocker & prostaglandin analogue) preservative free eyedrop, in adults. **Green** TLS.
- [Infliximab 120mg/1m solution for injection pre-filled pen/syringe](#) for subcutaneous injection. Added as an option for use in inflammatory bowel disease in accordance with local pathways. **Red** TLS.

New and Updated Shared Care Agreements and Prescribing Guidance

- **Updated** – Dementia drugs (donepezil, galantamine, memantine, rivastigmine) aligned across BSW with **AmberSCA** TLS. The SCA that GPs in BaNES and Wiltshire have been using has now been extended to include Swindon practices: [BSW/AWP Shared Care Agreement for Dementia](#)
Note that donepezil can continue to be initiated in primary care (Green TLS) in Wiltshire where there is a historic dementia LES in place and prescribers have received extra education and training to diagnose dementia.
- **New** - Acenocoumarol – aligned for BSW with **Amber** TLS. Also see [Acenocoumarol Information for Healthcare Professionals](#).
- **New** – [BSW insulin formulary](#). Guidance to support prescribing of insulin in T1D and T2D across BSW; prepared in collaboration with local specialist diabetes teams. BSWFormulary website has also been updated [here](#)

What the BSW CCG formulary team are currently working on

- Working with BSW Diabetes Specialist Pharmacist and local teams to:
 - produce local guidelines for glucose management in T2 diabetes in adults
 - produce guidance on safe initiation of SGLT2s in T2 diabetes in adults
 - summarise locally approved use of SGLT2s for their various licensed indications
 - summarise pharmacotherapy for chronic kidney disease in primary care
- Working with CAMHS on guidance and process for the use of SSRIs for first and second-line use in the treatment of depression in <18 years of age.
- Reviewing the national NHSE [Shared Care Protocols](#) for implementation locally. The BSW APC has prioritised adoption of these according to existing local protocols (and their date of review) and patient safety factors. As a result, amiodarone and valproate have been selected for implementation.



Bath and North East Somerset,
Swindon and Wiltshire Together

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems and Optimise Profiles are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswicb.formulary@nhs.net